Please use this identifier to cite or link to this item:
|Type:||Artigo de periódico|
|Title:||Efficacy of liposome-encapsulated mepivacaine for infiltrative anesthesia in volunteers|
de Araujo, DR
de Paula, E
|Abstract:||This blinded crossover study evaluated the efficacy and pain sensitivity evoked by a previously reported liposome-encapsulated mepivacaine formulation (Araujo et al., 2004). Thirty healthy volunteers received an intraoral injection (1.8 mL), at four different sessions, of the following formulations:2% mepivacaine with 1:100,000 epinephrine (MVC2%EPI), 3% mepivacaine (MVC3%), and 2 and 3% liposome-encapsulated mepivacaine (MVC2%LUV and MVC3%LUV). Latency period and duration of anesthesia were assessed by an electrical pulp tester and injection discomfort by a visual analog scale (VAS). Data were analyzed with Tukey-Kramer and Friedman tests (P < 0.05). No significant difference was found regarding latency period (in minutes) among the formulations (P > 0.05). The duration of anesthesia after the injection of MVC3%LUV was higher than the one obtained after the infiltration of MVC2%LUV and of MVC3% (P < 0.05). However, the duration of anesthesia obtained with MVC3% did not differ from the one obtained with MVC2%LUV (P > 0.05). MVC3%LUV showed lower VAS median values than MVC2%EPI (P < 0.05), and there were no significant differences among the others formulations. Liposome-encapsulated 3% mepivacaine showed longer duration of anesthesia, in comparison to the commercial formulation of MVC3%. MVC2%LUV was able to produce a similar duration of anesthesia as the 3% commercial formulation, despite the 50% decrease in the anesthetic concentration. Thus, the encapsulation of mepivacaine increased the duration of anesthesia and reduced the injection discomfort caused by vasoconstrictor-associated formulations in healthy volunteers.|
|Appears in Collections:||Unicamp - Artigos e Outros Documentos|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.